Nature Communications (Jan 2021)
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
- Rajasekharan Somasundaram,
- Thomas Connelly,
- Robin Choi,
- Hyeree Choi,
- Anastasia Samarkina,
- Ling Li,
- Elizabeth Gregorio,
- Yeqing Chen,
- Rohit Thakur,
- Mohamed Abdel-Mohsen,
- Marilda Beqiri,
- Meaghan Kiernan,
- Michela Perego,
- Fang Wang,
- Min Xiao,
- Patricia Brafford,
- Xue Yang,
- Xiaowei Xu,
- Anthony Secreto,
- Gwenn Danet-Desnoyers,
- Daniel Traum,
- Klaus H. Kaestner,
- Alexander C. Huang,
- Denitsa Hristova,
- Joshua Wang,
- Mizuho Fukunaga-Kalabis,
- Clemens Krepler,
- Fang Ping-Chen,
- Xiangyang Zhou,
- Alexis Gutierrez,
- Vito W. Rebecca,
- Prashanthi Vonteddu,
- Farokh Dotiwala,
- Shashi Bala,
- Sonali Majumdar,
- Harsh Dweep,
- Jayamanna Wickramasinghe,
- Andrew V. Kossenkov,
- Jorge Reyes-Arbujas,
- Kenisha Santiago,
- Tran Nguyen,
- Johannes Griss,
- Frederick Keeney,
- James Hayden,
- Brian J. Gavin,
- David Weiner,
- Luis J. Montaner,
- Qin Liu,
- Lukas Peiffer,
- Jürgen Becker,
- Elizabeth M. Burton,
- Michael A. Davies,
- Michael T. Tetzlaff,
- Kar Muthumani,
- Jennifer A. Wargo,
- Dmitry Gabrilovich,
- Meenhard Herlyn
Affiliations
- Rajasekharan Somasundaram
- The Wistar Institute
- Thomas Connelly
- The Wistar Institute
- Robin Choi
- The Wistar Institute
- Hyeree Choi
- The Wistar Institute
- Anastasia Samarkina
- The Wistar Institute
- Ling Li
- The Wistar Institute
- Elizabeth Gregorio
- The Wistar Institute
- Yeqing Chen
- The Wistar Institute
- Rohit Thakur
- Division of Cancer Epidemiology and Genetics, National Cancer Institute
- Mohamed Abdel-Mohsen
- The Wistar Institute
- Marilda Beqiri
- The Wistar Institute
- Meaghan Kiernan
- The Wistar Institute
- Michela Perego
- The Wistar Institute
- Fang Wang
- The Wistar Institute
- Min Xiao
- The Wistar Institute
- Patricia Brafford
- The Wistar Institute
- Xue Yang
- The Wistar Institute
- Xiaowei Xu
- Department of Pathology and Medicine, University of Pennsylvania
- Anthony Secreto
- Department of Medicine, Stem Cell and Xenograft Core, University of Pennsylvania
- Gwenn Danet-Desnoyers
- Department of Medicine, Stem Cell and Xenograft Core, University of Pennsylvania
- Daniel Traum
- Department of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania
- Klaus H. Kaestner
- Department of Genetics and Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania
- Alexander C. Huang
- Department of Pathology and Medicine, University of Pennsylvania
- Denitsa Hristova
- The Wistar Institute
- Joshua Wang
- The Wistar Institute
- Mizuho Fukunaga-Kalabis
- The Wistar Institute
- Clemens Krepler
- The Wistar Institute
- Fang Ping-Chen
- The Wistar Institute
- Xiangyang Zhou
- The Wistar Institute
- Alexis Gutierrez
- The Wistar Institute
- Vito W. Rebecca
- The Wistar Institute
- Prashanthi Vonteddu
- The Wistar Institute
- Farokh Dotiwala
- The Wistar Institute
- Shashi Bala
- The Wistar Institute
- Sonali Majumdar
- The Wistar Institute
- Harsh Dweep
- The Wistar Institute
- Jayamanna Wickramasinghe
- The Wistar Institute
- Andrew V. Kossenkov
- The Wistar Institute
- Jorge Reyes-Arbujas
- The Wistar Institute
- Kenisha Santiago
- The Wistar Institute
- Tran Nguyen
- The Wistar Institute
- Johannes Griss
- Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna
- Frederick Keeney
- The Wistar Institute
- James Hayden
- The Wistar Institute
- Brian J. Gavin
- The Wistar Institute
- David Weiner
- The Wistar Institute
- Luis J. Montaner
- The Wistar Institute
- Qin Liu
- The Wistar Institute
- Lukas Peiffer
- University of Duisburg-Essen
- Jürgen Becker
- University of Duisburg-Essen
- Elizabeth M. Burton
- Department of Surgical Oncology, MD Anderson Cancer Center
- Michael A. Davies
- Department of Melanoma Medical Oncology, University of California
- Michael T. Tetzlaff
- Department of Pathology and Dermatology, University of California
- Kar Muthumani
- The Wistar Institute
- Jennifer A. Wargo
- Department of Surgical Oncology, MD Anderson Cancer Center
- Dmitry Gabrilovich
- AstraZeneca
- Meenhard Herlyn
- The Wistar Institute
- DOI
- https://doi.org/10.1038/s41467-020-20600-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Immune checkpoint therapies (ICT) are promising for treating various cancers, but response rates vary. Here the authors show, in mouse models, that tumor-infiltrating mast cells colocalize with regulatory T cells, coincide with local reduction of MHC-I and CD8 T cells, and is associated with resistance to ICT, which can be reversed by c-kit inhibitor treatment.
